Sinotherapeutics Inc., a specialty pharmaceutical company, research, develops, manufactures, and commercializes generic and formulation products in China. The company's products are indicated for infection, oncology and rheumatology, gastroenterology and metabolism, neurology, cardiology, and nephrology. It offers posaconazole delayed-release tablets; olaparib, exemestane, and tofacitinib extended-release tablets; and mesalamine delayed-release, dapagliflozin and metformin hydrochloride sustained-release, sitagliptin and metformin hydrochloride sustained-release tablets, and ursodeoxycholic ACID Capsules. The company also provides bupropion hydrochloride extended-release tablets, and paroxetine and pregabalin extended-release tablets; propafenone hydrochloride extended-release capsules; and sevelamer carbonate tablets. Sinotherapeutics Inc. was founded in 2012 and is headquartered in Shanghai, China.
Frequently asked questions
What sector does Sinotherapeutics Inc. A (688247) operate in?
Sinotherapeutics Inc. A belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Sinotherapeutics Inc. A (688247) current stock price?
As of the latest data, Sinotherapeutics Inc. A stock price is CN¥8.77, with a previous close of CN¥8.77.
What is Sinotherapeutics Inc. A (688247) current market capitalization?
Sinotherapeutics Inc. A market cap is approximately 3.98 billion.
What is Sinotherapeutics Inc. A (688247) Earnings Per Share (EPS)?
The trailing EPS is CN¥0.08.
What is Sinotherapeutics Inc. A (688247) Price-to-Earnings (P/E) ratio?
Sinotherapeutics Inc. A current P/E ratio is 109.63.
Does Sinotherapeutics Inc. A (688247) pay dividends?
Yes. Sinotherapeutics Inc. A pays semiannual dividends with an annualized yield of 0.23% and an estimated annual payout of CN¥0.02 per share.
When is the next ex-dividend date for Sinotherapeutics Inc. A (688247)?
The next ex-dividend date is scheduled for December 26, 2026.
What is Sinotherapeutics Inc. A (688247) beta (volatility) score?
Sinotherapeutics Inc. A has a beta of 0.089, indicating lower volatility than the overall market.
